Date: 2017-07-30
Type of information: Licensing agreement
Compound: antibody therapies for the treatment of various gastrointestinal diseases, cancers and other disorders
Company: HiFiBiO Therapeutics (USA - MA) Takeda Pharmaceutical (Japan)
Therapeutic area: Cancer - Oncology - Gastrointestinal diseases - Digestive diseases
Type agreement: research - licensing
Action mechanism:
Disease:
Details:
- • On July 30, 2018, HiFiBiO Therapeutics announced a multi-target agreement with Takeda Pharmaceutical to enable the discovery of breakthrough antibody therapies to potentially treat various gastrointestinal diseases, cancers and other disorders. According to the agreement, scientists from both companies will work together to discover antibodies against Takeda’s targets using HiFiBiO Therapeutics’ single-cell screening capabilities. Takeda will be responsible for the preclinical and clinical development of the discovered antibodies.
Financial terms:
- HiFiBiO Therapeutics will receive upfront, R&D, milestone, and royalty payments based on antibodies delivered to Takeda for development and commercialization. Specific financial terms of the transaction were not disclosed.
Latest news:
Is general: Yes
